Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 19 de 19
Filter
1.
Joint Bone Spine ; 87(4): 321-325, 2020 07.
Article in English | MEDLINE | ID: mdl-32147567

ABSTRACT

INTRODUCTION: To evaluate, factors associated with new ultrasonographic lesions of the anterior chest wall in spondyloarthritis (SpA) after a follow up of 5 years. METHODS: SpA Patients included in 2013 in a first study were evaluated five years later. Ultrasound B mode and power Doppler examination of the two sternoclavicular joints and the manubrio-sternal joint were performed by the same two examinators at baseline and five years later. The presence of erosion, synovitis, ankylosis, power Doppler signal, joint effusion and joint space narrowing were assessed blind of the first evaluation. RESULTS: Among the 131 patients at baseline, 58 patients were evaluated 5 years later. The mean age was 48.2±11.9 years old, with 86% of male and mainly an axial disease (78%). Patient characteristics are comparable to the original cohort. The most frequent lesions were ankylosis of the manubriosternal joint (38%) and erosions of the sternoclavicular joint (29%). 31 patients (53%) developed a new lesion of the ACW. There is a statistically significant association between new lesions of the ACW and higher ASDAS CRP (1,86±1,07 VS 3,0±2,17 P<0,01) and with CRP (5,34±7,85 VS 16,2±35, P=0,035) in the moment of the examination. There was no baseline factor associated with the structural progression. CONCLUSION: The occurrence of new lesions of the anterior chest wall is associated with a higher disease activity and a higher CRP at 5 years.


Subject(s)
Spondylarthritis , Synovitis , Thoracic Wall , Adult , Humans , Male , Middle Aged , Prospective Studies , Spondylarthritis/diagnostic imaging , Synovitis/diagnostic imaging , Thoracic Wall/diagnostic imaging , Ultrasonography
2.
Joint Bone Spine ; 87(3): 225-228, 2020 May.
Article in English | MEDLINE | ID: mdl-32007650

ABSTRACT

18F-fluoro deoxy glucose PET scanner (18F-FDG-PET-CT) has shown its interest in the diagnosis of polymyalgia rheumatica (PMR) and makes possible to evaluate the metabolic activity of the entire musculoskeletal system and in particular muscular structures. The purpose of this study was to evaluate muscle involvement using 18F-FDG-PET-CT in the case of PMR, compared to a non PMR population. METHODS: This is a monocentric retrospective study of patients with PMR (ACR/EULAR 2012 criteria) who had an 18F-FDG-PET-CT examination. A control group composed of subjects without rheumatological manifestations who had such an examination as part of neoplastic research or follow-up of neoplastic diseases was also evaluated. The PET assessment included 17 sites suggesting a PMR, as previously reported. Areas of muscle hypermetabolism were classified in the same way according to the same semi quantitative classification. Muscle activity sites were identified. A comparison of patients with PMR with and without muscle damage was performed using the exact Mann-Whitney or Fisher test. RESULTS: Two hundred and one cases were examined, involving 101 PMRs (mean age 68.6 years) and 100 controls (mean age 67.7 years). Overall, PET muscle damage was observed in 34 cases (34%) in PMR and 10 cases (10%) in controls (P=0.004). Lesions are bi or multi-focal in half of the cases. The affected muscle sites are: spinal muscles 19, scapular girdle 14, pelvic girdle 13, and thigh 6. Fasciitis was found in 3 cases. In patients with PMR, PET muscle involvement was not associated with age, CRP or overall PMR PET score. CONCLUSION: Muscle damage assessed by 18F-Fluorodeoxyglucose PET-CT is common in PMR (1/3 of cases), located at the usual sites of disease symptoms, without association with age, CRP levels or the overall PET PMR score. The muscle must be carefully evaluated during a PET examination in cases of PMR.


Subject(s)
Fluorodeoxyglucose F18 , Polymyalgia Rheumatica , Aged , Humans , Muscles , Polymyalgia Rheumatica/diagnostic imaging , Positron Emission Tomography Computed Tomography , Retrospective Studies , Spine
3.
Eur J Rheumatol ; 6(3): 122-125, 2019 07.
Article in English | MEDLINE | ID: mdl-31329539

ABSTRACT

OBJECTIVE: Septic sacroiliitis is a difficult diagnosis rarely considered in an emergency in case of pelvic pain associated with fever. In these cases, a computed tomography (CT) is classically performed to exclude digestive or gynecological disorder, but the sacroiliac joint is not systematically analyzed. The aim of the present study was to detect the early signs of septic sacroiliitis on CT. METHODS: In a monocentric retrospective study, the characteristics, biology, and imaging of patients with septic sacroiliitis were analyzed. RESULTS: Seven cases of septic sacroiliitis were included in the study. For all patients, a CT scan with contrast-enhanced acquisitions of the pelvis was performed. The 4 early signs of septic sacroiliitis frequently not evocated by a radiologist in an emergency were highlighted as follows: fat infiltration in front of the sacroiliac joint (83%), anterior bulging of the sacroiliac capsule (46%), and piriformis and iliac muscles swelling (71% for both). All patients had at least one of these signs; 86% had at least 2 signs. Magnetic resonance imaging was performed for 5 out of 7 patients and confirmed the aspect of infectious sacroiliitis. CONCLUSION: Systematic analysis of the sacroiliac joint and adjacent muscles on pelvic CT scan is necessary to avoid the unrecognition of septic sacroiliitis in case of pelvic pain with fever.

5.
Clin Rheumatol ; 38(8): 2265-2273, 2019 Aug.
Article in English | MEDLINE | ID: mdl-30989408

ABSTRACT

INTRODUCTION/OBJECTIVES: Septic arthritis is a diagnostic and therapeutic emergency because of a high morbidity and mortality. Nevertheless, the etiologic diagnosis is often difficult. The aim of our study was to determine if serum procalcitonin was a discriminatory biomarker in case of arthritis of undetermined etiology. METHOD: Patients were separated in five groups: gouty arthritis, calcium pyrophosphate deposition arthritis, osteoarthritis or post-traumatic arthritis ("mechanical" arthritis), chronic inflammatory rheumatic arthritis, and septic arthritis. Levels of serum white blood cells, C-reactive protein and procalcitonin were measured. RESULTS: Ninety-eight patients were included: 18 in the "gout" group, 26 in the "calcium pyrophosphate deposition arthritis" group, 16 in the mechanical group, 18 in the "chronic inflammatory rheumatic" group, and 20 in the "sepsis" group. The area under the receiver operating characteristic curve of white blood cells, C-reactive protein, and procalcitonin levels to diagnose a septic arthritis were 0.69 (IC95% 0.55-0.83), 0.82 (IC95% 0.73-0.91), and 0.87 (IC95% 0.76-0.98) respectively. For a cutoff of 0.5 ng/ml, procalcitonin sensitivity, specificity, positive predictive value, negative predictive value, positive likelihood ratio and negative likelihood ratio were 65%, 91%, 65%, 91%, 7.2, and 0.4, respectively. Serum C-reactive protein and procalcitonin levels were correlated, were not different in sepsis or gout groups, and were higher in non-septic arthritis with poly-arthritis than with mono-arthritis (p < 0.05). CONCLUSIONS: Serum procalcitonin is a useful biomarker in arthritis management with diagnosis performances higher than those of other biomarkers (white blood cells, C-reactive protein).Key Points• Diagnostic performances of serum procalcitonin level in septic arthritis are higher than those of serum C-reactive protein or white blood cells levels.• Serum procalcitonin levels are not different in septic arthritis or gouty arthritis.• Serum procalcitonin levels are higher in non-septic arthritis with poly-arthritis than with mono-arthritis.


Subject(s)
Arthritis, Infectious/blood , Arthritis, Infectious/microbiology , Procalcitonin/blood , Rheumatology/standards , Aged , Aged, 80 and over , Arthritis, Gouty/blood , Biomarkers/blood , C-Reactive Protein/analysis , Calcium Pyrophosphate/metabolism , Female , Humans , Inflammation , Leukocytes/cytology , Male , Middle Aged , Osteoarthritis/blood , Predictive Value of Tests , Prospective Studies , Protein Precursors/blood , ROC Curve , Rheumatic Fever/blood , Sensitivity and Specificity
6.
Joint Bone Spine ; 86(2): 159-163, 2019 03.
Article in English | MEDLINE | ID: mdl-29787813

ABSTRACT

Ankylosing spondylitis (AS) is a chronic inflammatory joint disease that involves the entheses, causing inflammatory pain and functional impairments. Patients may experience extraarticular manifestations such as uveitis, psoriasis, and inflammatory bowel disease. These, together with the increased risk of cardiovascular disease and osteoporosis and the development of spinal fusion, are the main determinants of adverse disease outcomes. As with many systemic inflammatory diseases, AS is associated with excess cardiovascular mortality due to increased risks of myocardial infarction, stroke, and venous thromboembolism. Studies of markers for subclinical atheroma (endothelial dysfunction, arterial stiffness, and intima-media thickness) have shown earlier onset of arterial disease compared to healthy controls, with the difference being greatest for patients with active AS. The potential vascular effects of drugs used to treat AS have not been established. Few studies have focused on nonsteroidal antiinflammatory drugs and biologics in patients with AS, and their results do not conclusively establish a beneficial or deleterious effect in axial spondyloarthritis. Statins have been found to improve endothelial dysfunction and to decrease mortality. The latest EULAR recommendations on cardiovascular risk management in patients with inflammatory joint disease indicate that statins should be used in compliance with national guidelines.


Subject(s)
Anti-Inflammatory Agents, Non-Steroidal/therapeutic use , Cardiovascular Diseases/epidemiology , Cause of Death , Musculoskeletal Pain/drug therapy , Spondylitis, Ankylosing/diagnosis , Spondylitis, Ankylosing/epidemiology , Aged , Cardiovascular Diseases/diagnosis , Carotid Intima-Media Thickness , Comorbidity , Female , Humans , Male , Middle Aged , Musculoskeletal Pain/diagnosis , Prevalence , Prognosis , Risk Assessment , Severity of Illness Index , Spondylarthropathies/diagnosis , Spondylarthropathies/drug therapy , Spondylarthropathies/epidemiology , Spondylitis, Ankylosing/drug therapy , Survival Analysis , Vascular Stiffness/physiology
7.
Clin Rheumatol ; 38(2): 591-596, 2019 Feb.
Article in English | MEDLINE | ID: mdl-30328022

ABSTRACT

Dactylitis is a frequent disabling feature of psoriatic arthritis (PsA). Therapeutic strategy on dactylitis is not really codified. We performed a complementary literature review (since a previous one in 2014) of efficacy of new treatments recently used in PsA on this specific clinical manifestation. Eleven publications were retained (4697 patients). In the randomized double-blind placebo-controlled trials analyzed, authors declared ustekinumab, ixekizumab, adalimumab, and apremilast efficient. Secukinumab, clazakizumab, abatacept, and tofacitinib were promising. Brodalumab was ineffective. Calculations of odds ratios for residual dactylitis were significant for clazakizumab 100 mg and secukinumab in anti-TNF-naïve population. Homogenization of dactylitis assessment and use of this criterion as primary outcome are necessary to have better data on treatment efficacy in the future.


Subject(s)
Antirheumatic Agents/therapeutic use , Arthritis, Psoriatic/drug therapy , Biological Products/therapeutic use , Tenosynovitis/drug therapy , Arthritis, Psoriatic/complications , Humans , Randomized Controlled Trials as Topic , Tenosynovitis/etiology , Treatment Outcome , Tumor Necrosis Factor-alpha/antagonists & inhibitors
9.
Clin Rheumatol ; 37(3): 819-823, 2018 Mar.
Article in English | MEDLINE | ID: mdl-29380162

ABSTRACT

The aim of this study was to evaluate the impact of age on the therapeutic response to prednisone. This was a retrospective, monocentric study. We included patients diagnosed with PMR, according to ACR 2012 criteria. Patients were classified into two groups according to age (above or below 60 years old). We registered demographic, clinical, biological, imaging data, and therapeutic response profile. Local inflammation was evaluated at baseline with PET/CT imaging score. The treatment was standardised. The main endpoint was a corticosteroid dependence defined by the recurrence of PMR symptoms and/or the increase of CRP at two times. We included 14 patients younger than 60 years old (mean age 54 ± 0.8) and 28 patients older than 60 (mean age 75.8 ± 1.5). The "young PMR" group was mainly male (60 vs 27%; p < 0.05). Both groups were similar regarding morning stiffness, disease duration, WBC count, and CRP. The intensity of FDG uptake was lower (score of 16.9 ± 1.7 vs 26.5 ± 3.0; p < 0.05), there were more dependence on corticosteroids (60 vs 20%; p < 0.05) and methotrexate was more necessary (35 vs 6.5%; p < 0.05) in "young PMR" group. Young patients diagnosed with PMR are mostly men, are more dependent on corticosteroids, and have a lower PET-CT score at baseline in comparison to elderly patients diagnosed with PMR.


Subject(s)
Glucocorticoids/therapeutic use , Polymyalgia Rheumatica/drug therapy , Prednisone/therapeutic use , Age Factors , Aged , Female , Humans , Male , Middle Aged , Polymyalgia Rheumatica/diagnostic imaging , Positron Emission Tomography Computed Tomography , Prognosis , Retrospective Studies , Treatment Outcome
14.
Expert Opin Biol Ther ; 17(9): 1173-1181, 2017 09.
Article in English | MEDLINE | ID: mdl-28682112

ABSTRACT

INTRODUCTION: Axial spondyloarthritis is an inflammatory rheumatic disease causing back pain, functional impairment and potential ankylosis in the advanced stage. In this context, TNF blockers have been a major therapeutic advance. Etanercept is a soluble recombinant TNF receptor fusion protein in this vain. Areas covered: The aim of this review is to summarize the current published data concerning the efficacy and tolerance of etanercept in axial spondyloarthrits. The authors performed a systematic review on PubMed, using 'etanercept' and 'spondyloarthritis', 'axial spondyloarthritis' or 'ankylosing spondylitis' keywords. Expert opinion: Etanercept showed clinical efficacy on the axial (non-radiographic and radiographic) and peripheral manifestations (peripheral arthritis and enthesitis) of axial spondyloarthritis (Ax-SpA). Among the extra-articular manifestations, it works on psoriasis but not on inflammatory bowel disease, with a lack of efficacy data in anterior uveitis. Etanercept also demonstrated an interesting tolerance profile and good drug survival rates after 5 years. Etanercept was also shown to reduce MRI inflammation on the spine and the sacroiliac joints. However, like other TNF blockers, its impact on radiographic progression could not be fully demonstrated. In the context of upcoming new biologic targeted treatments, head-to-head and longer-term randomized controlled trials are now required to further define the role of etanercept in spondyloarthritis treatment strategies.


Subject(s)
Etanercept/therapeutic use , Immunosuppressive Agents/therapeutic use , Spondylarthritis/drug therapy , Clinical Trials as Topic , Crohn Disease/etiology , Disease Progression , Etanercept/adverse effects , Humans , Immunosuppressive Agents/adverse effects , Psoriasis/drug therapy , Receptors, Tumor Necrosis Factor/genetics , Receptors, Tumor Necrosis Factor/metabolism , Spondylarthritis/epidemiology , Spondylarthritis/pathology , Spondylitis, Ankylosing/drug therapy , Spondylitis, Ankylosing/pathology
16.
Article in English | MEDLINE | ID: mdl-27688712

ABSTRACT

OBJECTIVES: The objective of this study is to obtain pilot data from daily practice conditions of a viscosupplement made of a cross-linked high-molecular-weight hyaluronic acid (HA) combined with mannitol in patients with knee osteoarthritis (KOA). METHODS: The data of 40 consecutive patients, 29 women and 11 men, who were prospectively followed up for 6 months, using a standardized procedure, were retrospectively analyzed. All patients have received a single intra-articular injection of HAnox-M-XL (4.4 mL), viscosupplement made of a cross-linked HA (16 mg/mL) + mannitol (35 mg/mL), in the target knee. The primary outcome was safety. The secondary end points included 3- and 6-month change in the WOMAC pain (0-50) and WOMAC total (0-240) and patient's global assessment (PGA). Patient's self-assessment of treatment efficacy (0-3) and analgesic consumption were obtained at months 3 and 6. An intent-to-treat analysis was performed. RESULTS: Mean (SD) age was 60.7 (13.9) years, and mean BMI was 28.6 (5.0). Kellgren-Lawrence radiological grade was I/II and III/IV in 13 and 27 of the subjects, respectively. The average WOMAC pain and WOMAC total scores at baseline were 21.5 (9.8) and 89.9 (42.8), respectively. Thirty-nine patients completed the follow-up. HAnox-M-XL was well tolerated; two patients experienced knee pain after injection, which resolved within three days. No treatment-related severe adverse event was reported. Mean (SD) variations in WOMAC pain and WOMAC total scores were -8.2 (8.9) and -38.4 (35.6), respectively, at month 6 (P = 0.001). PGA decreased from 5.5 (2.0) to 3.0 (2.2) (P = 0.006). Efficacy was rated as good or very good in 76.9% of the cases. Most of the regular analgesics users decreased their consumption. CONCLUSION: Treatment with one injection of 4.4 mL HAnox-M-XL is effective to alleviate KOA symptoms over six months, without safety concern. Controlled trials are needed to confirm these pilot data.

18.
Rheumatology (Oxford) ; 55(8): 1452-7, 2016 08.
Article in English | MEDLINE | ID: mdl-27107429

ABSTRACT

OBJECTIVES: To compare (18)F-fluoro-dexoxyglucose PET/CT (FDG-PET/CT) findings in patients with polymyalgia rheumatica (PMR) and controls without rheumatologic disease. METHODS: We retrospectively included 50 patients with a diagnosis of PMR as well as 53 patients with a neoplasm as a control group. All patients underwent FDG-PET/CT. Seventeen hotspots were analysed. We performed a semi-quantitative analysis of FDG uptake (4-point score from 0 to 3). The cut-offs for the number of sites with high activity and for FDG uptake score were assessed using receiver operating characteristics curves and odds ratios (ORs). RESULTS: The two groups were comparable for the median patient age (69.3 years for PMR vs 68.1 for controls). Significant differences between the two groups were found for FDG uptake score (1.12 vs 0.34, P < 0.00001) and for the number of sites with significant uptake (score ⩾ 2): 6.36 sites vs 1.49 sites (P < 0.00001). The presence of three or more sites with significant uptake was correlated with the diagnosis of PMR with 74% sensitivity and 79% specificity (OR = 10.8). For the FDG uptake score, the cut-off was 0.53 (sensitivity 80%, specificity 77%, OR = 13.6). We found significant differences in all sites for FDG uptake score and the number of sites with significant uptake, particularly marked for shoulders, ischial tuberosities and interspinous bursitis (P < 0.00001 for FDG uptake score). CONCLUSION: Our results suggest that the number of sites with significant FDG uptake and the uptake score could be relevant criteria for the diagnosis of PMR.


Subject(s)
Fluorodeoxyglucose F18 , Polymyalgia Rheumatica/diagnostic imaging , Radiopharmaceuticals , Aged , Aged, 80 and over , Epidemiologic Methods , Female , Humans , Male , Middle Aged , Positron Emission Tomography Computed Tomography/methods , Retrospective Studies
SELECTION OF CITATIONS
SEARCH DETAIL
...